Product Information
Registration Status: ActiveHEPATECT CP SOLUTION FOR INFUSION 50 IU/ML is approved to be sold in Singapore with effective from 2014-10-24. It is marketed by ESHCOL PHARMACEUTICAL GROUP SINGAPORE PTE LTD, with the registration number of SIN14652P.
This product contains Human Hepatitis B Immunoglobulin 50 iu/ml in the form of INFUSION, SOLUTION. It is approved for INTRAVENOUS use.
This product is manufactured by Biotest AG in GERMANY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indication
Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Mechanism of Action
In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Active Ingredient/Synonyms
HBIG | Hepatitis B Immune Globulin (Human) | Hepatitis B immune globulin human | Human hepatitis B immunoglobulin | Human hepatitis B virus immune globulin | Human hepatitis-B immunoglobulin | Hepatitis B Immune Globulin |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.